CliffBio
small molecule

TACROLIMUS

TACROLIMUS

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameTACROLIMUS
Active ingredientTACROLIMUS
StrengthEQ 5MG BASE/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TACROLIMUS patent cliff — loss of exclusivity — | CliffBio